Clinical trials: Bladder Cancer Treatment
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT00030498
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer
Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00867347
- Testing
- therapeutic conventional surgery, radiation therapy
- Where
- United Kingdom
- Volunteers
- 45 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
This phase II trial studies how well atezolizumab when given with glycosylated recombinant human interleukin-7 (CYT107) works in treating patients with urothelial carcinoma that has spread to nearby tissue or lymph nodes (locally…
- Conditions
- Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma
- Trial name
- NCT03513952
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 9 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
This phase II trial compares the effect of adding radiation therapy to an immunotherapy drug called pembrolizumab versus pembrolizumab alone in treating patients with urothelial cancer that has spread from where it first started…
- Conditions
- Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
- Trial name
- NCT04936230
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 83 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
This is a single-arm, multicenter study to evaluate the efficacy and safety of HX008 injection in patients with BCG-unresponsive non-muscle invasive bladder cancer.
- Trial name
- NCT04738630
- Testing
- HX008
- Where
- 5 sites in China
- Volunteers
- 110 people
- Sponsor
- Taizhou Hanzhong biomedical co. LTD
Recurrent Bladder Cancer, Stage IV Bladder Cancer
Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma
A multicenter, randomized, Phase 2 trial to study the effectiveness and feasibility of association of trastuzumab with combination chemotherapy in advanced or metastatic bladder cancer patients.
- Conditions
- Recurrent Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder
- Trial name
- CVH-CT02 (NCT01828736)
- Testing
- Trastuzumab, Gemcitabine, Carboplatin
- Where
- 15 sites in Belgium, France
- Volunteers
- 61 people
- Sponsor
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Bladder Cancer
Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent
Safety profile and to determine maximum tolerated dose of Sorafenib in combination with Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent
- Trial name
- SOGUG-07-01 (NCT00544609)
- Testing
- Sorafenib, Radiotherapy
- Where
- 3 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
This phase II trial tests whether sacituzumab govitecan given before radical cystectomy works in treating patients with non-urothelial bladder cancer.
- Conditions
- Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Trial name
- NCT05581589
- Testing
- Lymphadenectomy, Radical Cystectomy, Sacituzumab Govitecan
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Washington
Various Advanced Cancer
A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer
The purpose the study is to measure the effect of nivolumab (BMS-936558) in reducing tumor size in subjects with metastatic or unresectable bladder cancer.
- Trial name
- NCT02387996
- Testing
- Nivolumab
- Where
- 67 sites in United States, Australia and 9 more
- Volunteers
- 270 people
- Sponsor
- Bristol-Myers Squibb
Non-Muscle Invasive Bladder Carcinoma
Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer
This phase IV trial studies whether there is a relationship between how a patient is positioned while receiving bacillus Calmette Guerin (BCG) within the bladder (intravesical) and how long BCG stays in the bladder (dwell time)…
- Trial name
- NCT07474519
- Testing
- Accelerometry, BCG Solution, Electronic Health Record Review
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium
RATIONALE: Drugs used in chemotherapy, such as FR901228 (depsipeptide), work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00087295
- Testing
- Depsipeptide
- Volunteers
- 6 people
- Sponsor
- SWOG Cancer Research Network
Adenocarcinoma (NOS), Anal Cancer
DESTINY-PANTUMOUR04
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease…
- Conditions
- Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- DP-04 (NCT07124000)
- Testing
- Trastuzumab deruxtecan
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Non-muscle-invasive Bladder Cancer
Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer
Bacillus Calmette-Guerin (BCG) is the standard of care for high-risk patients with non-muscle invasive bladder cancer (NMIBC) after transurethral tumor resection.
- Trial name
- NCT05671900
- Testing
- Gemcitabine 1000 mg, Docetaxel 37.5g
- Where
- Croatia
- Volunteers
- 70 people
- Sponsor
- Clinical Hospital Centre Zagreb
Bladder Cancer
TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation
A multicentre observational study on treatment approaches and HER2 positive status prevalence in different stages of bladder cancer and PD-L1-positive status in metastatic bladder cancer in Russian Federation
- Trial name
- RIVERS (NCT07038928)
- Where
- 20 sites in Russia
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Superficial Bladder Cancer
Therapeutic Instillation of Mistletoe
The aim of this phase III study is to assess the efficacy of abnobaVISCUM® 900 compared with Mitomycin C (MMC) monotherapy in patients with superficial bladder carcinoma by evaluation of the time to tumor recurrence.
- Trial name
- TIM (NCT02106572)
- Testing
- abnobaVISCUM 900, Mitomycin C
- Where
- 5 sites in Egypt, Germany
- Volunteers
- 174 people
- Sponsor
- Abnoba Gmbh
Bladder Urothelial Carcinoma, Lymph Node Metastasis
Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC
This is a prospective, multicenter, Phase Ib clinical study designed to evaluate the safety and preliminary efficacy of propranolol combined with tislelizumab plus gemcitabine/cisplatin (GC) as neoadjuvant therapy for patients…
- Trial name
- NCT07353294
- Testing
- propranolol, Tislelizumab, gemcitabine
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Bladder (Urothelial, Transitional Cell) Cancer
A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection
This is a prospective, open label, multicenter clinical study of vediximab combined with PD-1 and radiation therapy for bladder preservation in MIBC patients with HER-2 high expression (IHC 2+or 3+), conducted in accordance with…
- Trial name
- DECIDING (NCT07142200)
- Testing
- Disitamab Vedotin, PD-1 inhibitor, radiotherapy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- RenJi Hospital
Bladder Urothelial Carcinoma
A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer
The researchers are doing this study to find out whether stereotactic body radiation therapy (SBRT) in combination with immunotherapy (cemiplimab with or without fianlimab) before cystectomy is an effective and safe treatment for…
- Trial name
- NCT07414992
- Testing
- Stereotactic body radiotherapy, Cemiplimab, Cemiplimab and Fianlimab
- Where
- 7 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Urothelial Carcinoma Bladder
Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer
This is a prospective, single-institution, single-arm, phase II clinical trial that tests a novel strategy of neoadjuvant Sasanlimab, an immune checkpoint inhibitor (ICI), in combination with stereotactic body radiation therapy…
- Trial name
- RAD-VACCINE (NCT05241340)
- Testing
- Sasanlimab, Stereotactic Body Radiation Therapy, Radical Cystectomy + pelvic lymph node dissection + urinary diversion
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- The Methodist Hospital Research Institute
Urinary Bladder Neoplasms, Woman
Urinary Continence of Female POPRC and OIN
To compare the urinary continence rate and long-term oncological outcomes of pelvic-organ preserving radical cystectomy (POPRC) with orthotopic ileal neobladder (OIN) versus standard radical cystectomy(SRC) with OIN.
- Conditions
- Urinary Bladder Neoplasms, Woman, Sexual Dysfunction, Physiological, Treatment Outcome
- Trial name
- NCT05325216
- Testing
- POPRC+OIN, SRC+OIN
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University